Hemogenyx Pharmaceuticals PLC
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,465.00 | 44.50 | 0.53% |
CAC 40 | 7,393.76 | 13.02 | 0.18% |
DAX 40 | 20,024.66 | 115.52 | 0.58% |
Dow JONES (US) | 42,297.04 | 247.18 | -0.58% |
FTSE 100 | 8,260.09 | 87.07 | 1.07% |
HKSE | 19,623.32 | 436.63 | -2.18% |
NASDAQ | 19,198.96 | 111.83 | -0.58% |
Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
S&P 500 | 5,850.25 | 31.38 | -0.53% |
S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
SSE Composite Index | 3,262.56 | 89.20 | -2.66% |